Category Research

Biogen and City Therapeutics Partner on Novel RNAi Therapy Research

Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc., a private biopharmaceutical company at the forefront of RNA interference…

Read MoreBiogen and City Therapeutics Partner on Novel RNAi Therapy Research

Merck Highlights Cutting-Edge Advances in Treating Advanced Cancers and Rare Tumors at ASCO 2025

Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer care through the presentation of groundbreaking clinical data across a…

Read MoreMerck Highlights Cutting-Edge Advances in Treating Advanced Cancers and Rare Tumors at ASCO 2025

Viatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch

A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…

Read MoreViatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch

Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…

Read MoreImfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

Enhertu + THP Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11

Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab, and pertuzumab (THP), has shown a significantly improved safety profile…

Read MoreEnhertu + THP Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11